Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies.
immunomodulatory therapies
multiple sclerosis
serum neurofilament
therapy-response marker
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
28 Aug 2020
28 Aug 2020
Historique:
received:
09
07
2020
revised:
24
08
2020
accepted:
25
08
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
3
9
2020
Statut:
epublish
Résumé
Serum neurofilament light chain (NfL) has been shown to correlate with neuroaxonal damage in multiple sclerosis (MS) and various other neurological diseases. While serum NfL is now regularly reported in clinical approval studies, there is a lack of longitudinal data from patients treated with established basic immunotherapies outside of study conditions. In total, 34 patients with early relapsing-remitting MS (RRMS) were included. The follow-up period was 24 months with regular follow-up visits after 3, 6, 9, 12 and 18 months. Therapy with glatiramer acetate was initiated in 20 patients and with interferon-beta in 12 patients. The disease course was monitored by the events of relapses, Expanded Disability Status Scale (EDSS) score and MRI parameters. Overall, serum NfL levels were higher at time points with a current relapse event than at time points without relapse (12.8 pg/mL vs. 9.7 pg/mL,
Identifiants
pubmed: 32872144
pii: biomedicines8090312
doi: 10.3390/biomedicines8090312
pmc: PMC7555392
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Neurology. 2016 Sep 13;87(11):1068-9
pubmed: 27521432
J Immunol Methods. 2003 Jul;278(1-2):179-90
pubmed: 12957406
Sci Rep. 2020 Jun 25;10(1):10381
pubmed: 32587320
Neurology. 2009 Dec 1;73(22):1914-22
pubmed: 19949037
Eur Neurol. 2014;72(3-4):132-41
pubmed: 25095894
Neurology. 2016 Sep 13;87(11):1076-84
pubmed: 27521440
Mult Scler. 2013 Oct;19(12):1597-603
pubmed: 23529999
Mult Scler. 2016 Oct;22(12):1550-1559
pubmed: 26754800
JAMA Neurol. 2019 Jun 17;:
pubmed: 31206160
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
Mult Scler. 2020 May;26(6):659-667
pubmed: 30912689
EBioMedicine. 2020 Jun;56:102807
pubmed: 32460167
Nat Commun. 2020 Feb 10;11(1):812
pubmed: 32041951
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):
pubmed: 28373358
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Mult Scler. 2020 Feb;26(2):210-219
pubmed: 30570436
Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61
pubmed: 27071153
Mult Scler. 2006 Apr;12(2):143-8
pubmed: 16629417
Eur Neurol. 2011;65(3):164-9
pubmed: 21372576
Ann Neurol. 2011 Jan;69(1):83-9
pubmed: 21280078
Neurol Neuroimmunol Neuroinflamm. 2019 Apr 08;6(3):e555
pubmed: 31119188
J Neurol. 2019 Feb;266(2):386-397
pubmed: 30515631
Sci Rep. 2018 Oct 4;8(1):14798
pubmed: 30287870
Lancet. 2002 Apr 6;359(9313):1221-31
pubmed: 11955556
Sci Rep. 2020 Jun 8;10(1):9161
pubmed: 32514050
Neurology. 2017 Feb 28;88(9):826-831
pubmed: 28148632
Nat Biotechnol. 2010 Jun;28(6):595-9
pubmed: 20495550
Ann Clin Transl Neurol. 2019 May 28;6(6):1081-1089
pubmed: 31211172
J Neuroinflammation. 2018 Jul 18;15(1):209
pubmed: 30021640
Neurology. 2017 Nov 28;89(22):2230-2237
pubmed: 29079686
J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881
pubmed: 30967444
J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1324-1330
pubmed: 31611264
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Mult Scler. 2019 Apr;25(5):678-686
pubmed: 29542376
Mult Scler. 2012 May;18(5):552-6
pubmed: 22492131